Oral administration. Take immediately before going to bed, and only if you are able to get a full night's sleep (7 to 8 hours) before you need to be active again. Do not take with or immediately after a heavy, high-fat meal.

Eszopiclone is a nonbenzodiazepine hypnotic that is a pyrrolopyrazine derivative of the cyclopyrrolone class. It is thought to act by interacting with the GABA-A receptor complex at a site distinct from, but allosterically coupled to, the benzodiazepine binding site. This interaction enhances the effect of GABA, an inhibitory neurotransmitter, leading to sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxant properties.

• •Known hypersensitivity to Eszopiclone or any component of the formulation.
• •Patients who have experienced complex sleep behaviors (e.g., sleepwalking, sleep-driving, engaging in other activities while not fully awake) after taking Eszopiclone.
• •Severe hepatic impairment.

Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.

Symptoms of overdose include excessive sedation, confusion, ataxia, slurred speech, respiratory depression, and coma. Treatment is primarily supportive; gastric lavage or activated charcoal may be considered if ingested recently. Flumazenil may be considered in severe cases, but has not been evaluated in Eszopiclone overdose.

Pregnancy Category C. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown if Eszopiclone is excreted in human milk; caution should be exercised when administered to a nursing mother.